Published in Biol Psychiatry on February 15, 2000
Riluzole to Treat Depression in Bipolar Disorder | NCT00054704
Clinical Trial of Memantine for Major Depression | NCT00040261
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79
Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry (2010) 2.08
Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One (2009) 1.78
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 1.69
Acute shift in glutamate concentrations following experimentally induced panic with cholecystokinin tetrapeptide--a 3T-MRS study in healthy subjects. Neuropsychopharmacology (2013) 1.67
Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 1.58
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 1.56
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.54
Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci (2010) 1.54
Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol (2015) 1.45
Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry (2010) 1.42
Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) (2004) 1.39
Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets (2013) 1.26
Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry (2011) 1.23
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry (2010) 1.21
Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl) (2003) 1.15
Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol (2009) 1.07
Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord (2010) 1.06
An excitatory synapse hypothesis of depression. Trends Neurosci (2015) 1.05
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One (2013) 1.04
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol (2008) 1.03
The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T ¹H-MRS study. Neuropsychopharmacology (2012) 1.03
Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02
Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J Psychopharmacol (2011) 1.02
Altered cerebral perfusion in executive, affective, and motor networks during adolescent depression. J Am Acad Child Adolesc Psychiatry (2013) 0.99
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology (2009) 0.99
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
The As and Ds of stress: metabolic, morphological and behavioral consequences. Eur J Pharmacol (2008) 0.98
Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration. Mol Psychiatry (2011) 0.97
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.97
Applications of multi-nuclear magnetic resonance spectroscopy at 7T. World J Radiol (2011) 0.93
Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extract. PLoS One (2014) 0.93
Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci (2014) 0.92
Regional cortical gray matter thickness differences associated with type 2 diabetes and major depression. Psychiatry Res (2010) 0.91
Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology (2005) 0.91
Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. J Affect Disord (2009) 0.91
Interoceptive dysfunction: toward an integrated framework for understanding somatic and affective disturbance in depression. Psychol Bull (2014) 0.90
Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90
A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry (2015) 0.90
Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci (2014) 0.88
Glutamate level detection by magnetic resonance spectroscopy in patients with post-stroke depression. Eur Arch Psychiatry Clin Neurosci (2011) 0.88
Increased glutamate levels in the medial prefrontal cortex in patients with postpartum depression. Neuropsychopharmacology (2012) 0.87
The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol (2009) 0.87
Two-dimensional J-resolved proton MR spectroscopy and prior knowledge fitting (ProFit) in the frontal and parietal lobes of healthy volunteers: assessment of metabolite discrimination and general reproducibility. J Magn Reson Imaging (2012) 0.86
Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. Brain Res Bull (2012) 0.85
Alcohol dependence-related increase of glial cell density in the anterior cingulate cortex of suicide completers. J Psychiatry Neurosci (2009) 0.85
Ambulatory sleep-wake patterns and variability in young people with emerging mental disorders. J Psychiatry Neurosci (2015) 0.85
Strain differences in the distribution of N-methyl-d-aspartate and gamma (gamma)-aminobutyric acid-A receptors in rat brain. Life Sci (2009) 0.84
Biological substrates underpinning diagnosis of major depression. Int J Neuropsychopharmacol (2013) 0.84
Reduced medial prefrontal N-acetyl-aspartate levels in pediatric major depressive disorder: a multi-voxel in vivo(1)H spectroscopy study. Psychiatry Res (2010) 0.84
Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. Behav Brain Res (2011) 0.84
Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. J Psychopharmacol (2009) 0.83
Electroconvulsive Treatment: Hypotheses about Mechanisms of Action. Front Psychiatry (2013) 0.83
Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression. Psychiatry Res (2009) 0.82
Glutamine deficiency in the prefrontal cortex increases depressive-like behaviours in male mice. J Psychiatry Neurosci (2013) 0.82
A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol (2015) 0.82
Distinct neurometabolic profiles are evident in the anterior cingulate of young people with major psychiatric disorders. Transl Psychiatry (2012) 0.81
Integration of ¹H NMR and UPLC-Q-TOF/MS for a comprehensive urinary metabonomics study on a rat model of depression induced by chronic unpredictable mild stress. PLoS One (2013) 0.81
Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom (2014) 0.81
Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? Neurosci Biobehav Rev (2012) 0.81
Glutamatergic system abnormalities in posttraumatic stress disorder. Psychopharmacology (Berl) (2015) 0.81
Choline in pediatric depression. Mcgill J Med (2006) 0.80
Increased GABA levels in medial prefrontal cortex of young adults with narcolepsy. Sleep (2008) 0.80
Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol (2014) 0.80
Phase-adjusted echo time (PATE)-averaging 1 H MRS: application for improved glutamine quantification at 2.89 T. NMR Biomed (2012) 0.79
Amitriptyline inhibits the activity of the rat glutamate transporter EAAT3 expressed in Xenopus oocytes. J Pharm Pharmacol (2009) 0.79
Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med Chem J (2010) 0.79
Neurochemical metabolites in prefrontal cortex in patients with mild/moderate levels in first-episode depression. Neuropsychiatr Dis Treat (2013) 0.79
Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: a proton magnetic resonance spectroscopy study. Schizophr Res (2014) 0.79
Proton magnetic resonance spectroscopy in depression. Indian J Psychiatry (2011) 0.79
Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res (2013) 0.79
Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules (2015) 0.79
Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression. Psychopharmacology (Berl) (2005) 0.78
Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J Psychiatry Neurosci (2017) 0.78
Functional and structural remodeling of glutamate synapses in prefrontal and frontal cortex induced by behavioral stress. Front Psychiatry (2015) 0.78
Cellular abnormalities in depression: evidence from postmortem brain tissue. Dialogues Clin Neurosci (2004) 0.78
Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Transl Psychiatry (2016) 0.78
AMPA receptor expression is increased post-mortem samples of the anterior cingulate from subjects with major depressive disorder. J Affect Disord (2011) 0.78
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry (2016) 0.77
Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). Epilepsy Behav (2013) 0.76
Stress as a one-armed bandit: Differential effects of stress paradigms on the morphology, neurochemistry and behavior in the rodent amygdala. Neurobiol Stress (2015) 0.76
Abnormal Anterior Cingulate N-Acetylaspartate and Executive Functioning in Treatment-Resistant Depression After rTMS Therapy. Int J Neuropsychopharmacol (2015) 0.76
Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett (2012) 0.76
Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities. Neuropsychopharmacology (2016) 0.76
Atypical Antidepressant Activity of 3,4-Bis(3,4-Dimethoxyphenyl) Furan-2,5-Dione Isolated from Heart Wood of Cedrus deodara, in Rodents. Korean J Physiol Pharmacol (2014) 0.76
Increased Glutamate in Somatosensory Cortex in Functional Dyspepsia. Sci Rep (2017) 0.75
Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Sci Rep (2017) 0.75
Involvement of the glutamate/glutamine cycle and glutamate transporter GLT-1 in antidepressant-like effects of Xiao Yao san on chronically stressed mice. BMC Complement Altern Med (2017) 0.75
Reducing occupational stress with a B-vitamin focussed intervention: a randomized clinical trial: study protocol. Nutr J (2014) 0.75
Doxepin and imipramine but not fluoxetine reduce the activity of the rat glutamate transporter EAAT3 expressed in Xenopus oocytes. BMC Anesthesiol (2015) 0.75
Neurometabolic characteristics in the anterior cingulate gyrus of Alzheimer's disease patients with depression: a (1)H magnetic resonance spectroscopy study. BMC Psychiatry (2015) 0.75
Variations in myo-inositol in fronto-limbic regions and clinical response to electroconvulsive therapy in major depression. J Psychiatr Res (2016) 0.75
Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders. Dialogues Clin Neurosci (2002) 0.75
Fully automated macromolecule suppressed single voxel glutamate spectroscopy (FAMOUS SVGS). J Transl Med (2016) 0.75
An Exploratory Study of Spectroscopic Glutamatergic Correlates of Cortical Excitability in Depressed Adolescents. Front Neural Circuits (2016) 0.75
Main Effects of Diagnoses, Brain Regions, and their Interaction Effects for Cerebral Metabolites in Bipolar and Unipolar Depressive Disorders. Sci Rep (2016) 0.75
Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: A preliminary (1)H MRS study. Nutr Neurosci (2016) 0.75
Electroconvulsive therapy on severe obsessive-compulsive disorder comorbid depressive symptoms. Psychiatry Investig (2014) 0.75
Human cerebellar activity reflecting an acquired internal model of a new tool. Nature (2000) 4.29
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet (1998) 3.42
Differential signal transduction by five splice variants of the PACAP receptor. Nature (1993) 3.38
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci (1999) 2.76
Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol (1997) 2.16
Brain activation and hypothalamic functional connectivity during human non-rapid eye movement sleep: an EEG/fMRI study. Brain (2005) 2.07
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci (2000) 2.06
Low lumbar bone mineral density in patients with major depression. Am J Psychiatry (1994) 2.05
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res (1995) 1.94
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res (2000) 1.89
Transition of brain activation from frontal to parietal areas in visuomotor sequence learning. J Neurosci (1998) 1.85
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun (1995) 1.80
MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology (1999) 1.71
Diurnal variations in the human host response to endotoxin. J Infect Dis (1996) 1.71
Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol (1997) 1.53
Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. J Neurosci (1999) 1.52
Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol (2000) 1.51
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry (1995) 1.49
The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individuals. Acta Psychiatr Scand (2004) 1.46
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience (1998) 1.42
Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry (1999) 1.42
Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol (2002) 1.41
V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci (1995) 1.39
Comments on plasma fibrinogen levels measured by functional methods. Thromb Haemost (1994) 1.39
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology (Berl) (1995) 1.35
Behavioural performance in three substrains of mouse strain 129. Brain Res (1997) 1.33
Activation of human presupplementary motor area in learning of sequential procedures: a functional MRI study. J Neurophysiol (1996) 1.33
Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci (1993) 1.31
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res (2001) 1.31
"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol (2005) 1.31
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology (2007) 1.29
Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol (1993) 1.28
Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry (1999) 1.28
The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience (1994) 1.28
Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol (2000) 1.26
Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry (2003) 1.24
Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology (1997) 1.23
Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci (2001) 1.22
Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry (2005) 1.19
Gray matter-changes and correlates of disease severity in schizophrenia: a statistical parametric mapping study. Neuroimage (2001) 1.19
Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol (2001) 1.19
Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology (2002) 1.18
Progesterone receptor-mediated effects of neuroactive steroids. Neuron (1993) 1.18
Presupplementary motor area activation during sequence learning reflects visuo-motor association. J Neurosci (1999) 1.17
Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci (1995) 1.16
Influence of Epstein-Barr virus genomes on patient survival in Hodgkin's disease. Am J Clin Pathol (1992) 1.16
Fiber tracking from DTI using linear state space models: detectability of the pyramidal tract. Neuroimage (2002) 1.16
Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav (2013) 1.15
Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry (2008) 1.15
Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components. J Lab Clin Med (1974) 1.14
Placental glucose transporter expression is regulated by glucocorticoids. J Clin Endocrinol Metab (1999) 1.13
Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry (1999) 1.12
HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology (2008) 1.12
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry (2008) 1.12
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology (1998) 1.12
Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med (1984) 1.12
Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology (2001) 1.12
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J Clin Invest (1994) 1.11
[Patients with chronic pain syndromes. Impact of an individual outpatient therapy program on pain and health-related quality of life]. Schmerz (2010) 1.11
Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry (1996) 1.10
Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J (2000) 1.09
Neuropeptide S receptor gene -- converging evidence for a role in panic disorder. Mol Psychiatry (2010) 1.09
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology (2000) 1.09
Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency. Neurology (2004) 1.09
Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol (1996) 1.09
Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology (1993) 1.08
Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept (1995) 1.08
Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol (1994) 1.08
Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry (1987) 1.08
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology (1998) 1.07
The effect of the fibrinogen concentration and the leukocyte count on intravascular fibrin deposition from soluble fibrin monomer complexes. Thromb Haemost (1976) 1.07
A novel chronic social stress paradigm in female mice. Horm Behav (2010) 1.06
Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res (1998) 1.06
Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J (1995) 1.06
Laterality, somatotopy and reproducibility of the basal ganglia and motor cortex during motor tasks. Brain Res (2000) 1.06
Cortisol, ACTH, and cardiovascular response to a cognitive challenge paradigm in aging and depression. Am J Physiol (1995) 1.05
Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol (1993) 1.05
Forced swimming evokes a biphasic response in CREB phosphorylation in extrahypothalamic limbic and neocortical brain structures in the rat. Eur J Neurosci (2002) 1.05
Genome-wide association analysis of copy number variation in recurrent depressive disorder. Mol Psychiatry (2011) 1.05
gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem (1995) 1.04
The neural correlates and temporal sequence of the relationship between shock exposure, disturbed sleep and impaired consolidation of fear extinction. J Psychiatr Res (2010) 1.04
Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry (2006) 1.04
High constitutive NF-kappaB activity mediates resistance to oxidative stress in neuronal cells. J Neurosci (1998) 1.04
Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron (1994) 1.04
Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides (2001) 1.03
Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol (1999) 1.03
Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion? J Neurosci (1996) 1.02
Estimating the heritability of reporting stressful life events captured by common genetic variants. Psychol Med (2012) 1.01
Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry (1999) 1.01
Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol (1997) 1.01
Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol (1992) 1.01
Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. J Clin Psychiatry (2001) 1.01